Lymphoma-binding peptide

Renschler MF, Bhatt RR, Dower WJ, Levy R, Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma, Proc. Natl. Acad. Sci. USA, 91 3623-3267, 1994. 

Fig. 13.5 Proteasome inhibitors used (or intended) for the treatment of relapsed multiple myeloma, mantle cell lymphoma, and some other tumors. Structures of the peptide boronates bortezomib and the orally active MLN9708, the peptide epoxyketone carfilzomib, and the y-lactam-p-lactone bicyclics sallnosporamide A (marizomib) and omuralide (P-clastolactacystin), both derived from natural sources. The drugs inhibit normal proteasome action by binding to the p-subunit proteolytic sites in the 20S core (see Fig. 13.4)...

Shen, G.K., Zukoski, C.F., and Montgomery, D.W. (1992) A specific binding site in Nb2 node lymphoma cells mediates the effects of didemnin B, an immunosuppressive cyclic peptide. 7nt. J. Immunopharm., 14, 63-73. 

---